7X3M image
Entry Detail
PDB ID:
7X3M
Keywords:
Title:
Crystal structure of Aldo-keto reductase 1C3 complexed with compound S07045
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-03-01
Release Date:
2023-03-08
Method Details:
Experimental Method:
Resolution:
2.69 Å
R-Value Free:
0.22
R-Value Work:
0.18
R-Value Observed:
0.19
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Aldo-keto reductase family 1 member C3
Chain IDs:A, B
Chain Length:329
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment.
J.Med.Chem. 66 9537 9560 (2023)
PMID: 37409679 DOI: 10.1021/acs.jmedchem.3c00213

Abstact

Aldo-keto reductase 1C3 (AKR1C3) is correlated with tumor development and chemotherapy resistance. The catalytic activity of the enzyme has been recognized as one of the important factors in inducing anthracycline (ANT) resistance in cancer cells. Inhibition of AKR1C3 activity may provide a promising approach to restore the chemosensitivity of ANT-resistant cancers. Herein, a series of biaryl-containing AKR1C3 inhibitors has been developed. The best analogue S07-1066 selectively blocked AKR1C3-mediated reduction of doxorubicin (DOX) in MCF-7 transfected cell models. Furthermore, co-treatment of S07-1066 significantly synergized DOX cytotoxicity and reversed the DOX resistance in MCF-7 cells overexpressing AKR1C3. The potential synergism of S07-1066 over DOX cytotoxicity was demonstrated in vitro and in vivo. Our findings indicate that inhibition of AKR1C3 potentially enhances the therapeutic efficacy of ANTs and even suggests that AKR1C3 inhibitors may serve as effective adjuvants to overcome AKR1C3-mediated chemotherapy resistance in cancer treatment.

Legend

Protein

Chemical

Disease

Primary Citation of related structures